# 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study

Source: https://onco.cc/trials/nct06750419/  
OnCo record `nct06750419` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Zirconium-89 girentuximab run by Telix Pharmaceuticals (Innovations) Pty Limited in renal cell carcinoma, now recruiting.

## Summary

89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study is a phase 3 interventional study registered as NCT06750419 by Telix Pharmaceuticals (Innovations) Pty Limited, with 82 participants planned, started 2024-11-06. Conditions listed: Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06750419
- Phase: 3
- Setting: A Confirmatory, Open-label, Single-arm, Multi-centre Study to Evaluate Safety, Tolerability and Diagnostic Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) to Non-invasively Detect Clear Cell Renal Cell Carcinoma (ccRCC) by Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Chinese Patients With Indeterminate Renal Masses (ZIRCON-CP Study)
- Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
- Enrolled: 82

## Sources

- ClinicalTrials.gov NCT06750419: https://clinicaltrials.gov/study/NCT06750419

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Zirconium-89 girentuximab](https://onco.cc/drugs/girentuximab-zr89/)
- companies: [Telix Pharmaceuticals](https://onco.cc/companies/telix/)

---
JSON: https://onco.cc/api/v1/entities/nct06750419.json